Oxford Biomedica (NASDAQ:OXBDF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage currently has a $0.25 price objective on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 81.16% from the company’s current price.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Shares of Oxford Biomedica (NASDAQ OXBDF) opened at 0.138 on Wednesday. The firm’s market capitalization is $426.18 million. The stock has a 50 day moving average of $0.12 and a 200-day moving average of $0.12. Oxford Biomedica has a 1-year low of $0.11 and a 1-year high of $0.14.

WARNING: “Oxford Biomedica (OXBDF) Rating Increased to Buy at Zacks Investment Research” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/01/oxford-biomedica-oxbdf-rating-increased-to-buy-at-zacks-investment-research.html.

Oxford Biomedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

Receive News & Stock Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related stocks with our FREE daily email newsletter.